Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 197 clinical trials
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) (ReCOVER)

The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include assessments for evidence of remyelination in the anterior …

antihistamine
  • 51 views
  • 07 Oct, 2022
  • 1 location
Genomic Response of Human Immune and Non-Immune Cells to Glucocorticoids

Background The immune system defends the body against bacteria and other harmful invaders. But it can overact and attack healthy cells by mistake. The group of drugs called glucocorticoids (GCs) can calm down an overactive immune system. But they often cause negative side effects. Researchers want to learn how human …

Accepts healthy volunteers
  • 17 views
  • 21 Oct, 2022
  • 1 location
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

This study is an open, prospective, single arm, multi center exploratory basket clinical study. 20 refractory solid tumors patients with rescuable p53 mutation will be enrolled, and the efficacy and safety of arsenic trioxide in those patients will be evaluated.

  • 0 views
  • 24 May, 2021
  • 1 location
Dupilumab for Prevention of Recurrence of CRSwNP After ESS

The investigators believe that administering Dupilumab during the pre- and peri-operative period of surgery for chronic rhinosinusitis with nasal polyps (CRSwNP) will safely downregulate Type 2 inflammation of the healing sinus environment and will allow for better coordinated and more effective mucosal healing. Specifically, the investigators believe that endoscopic signs …

  • 1 views
  • 13 Jun, 2021
  • 1 location
A Phase I, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed OR Refractory Non-Hodgkin Lymphomas (R/R NHL).

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

hodgkin's disease
neutrophil count
rituximab
blood transfusion
  • 77 views
  • 28 Oct, 2022
  • 23 locations
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic

lymphoma
large b-cell lymphoma
btk inhibitor
diffuse large b-cell lymphoma
b-cell lymphoma
  • 0 views
  • 04 Oct, 2022
  • 45 locations
  • 1 views
  • 23 Oct, 2022
  • 138 locations
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)

This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of

tyrosine
TP53
  • 0 views
  • 24 Oct, 2022
  • 35 locations
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Neoplasms, and Myelofibrosis. Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis. CPI-0610 is a small molecule inhibitor of bromodomain and

myelodysplastic/myeloproliferative neoplasms
hypertension
acute leukemia
myeloproliferative disorder
ruxolitinib
  • 281 views
  • 30 May, 2022
  • 54 locations
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with relapsed or refractory small cell lung cancer. This study will be conducted

  • 0 views
  • 15 Jul, 2022
  • 30 locations